In addition to Tb927.11.3350, the T. brucei genome contains three other putative Tb927.11.3350 and Tb927.11.13000) have a similar domain organisation to the yeast TGES domain characteristic of the related cation transporting P-type ATPases, such as 3 2 3 yeast Pay2 (47), so its identity is unclear (Fig. 8A ).
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In addition to the Leishmania miltefosine transporter orthologue, Tb927.11.3350,
RNAi fragments targeting the flippases, Tb927.11.13000 and Tb927.6.3550, and the β -3 2 6 subunit, Tb927.11.13200, were enriched following selection in amphotericin-B, with 3 2 7
Tb927.11.13000 represented by 78% of mapped reads ( Fig. 8B ; Table S1 ). Targeted RNAi 3 2 8 depletion of Tb927.11.13000 led to a mild growth defect ( Fig. 8C ) and a more than two-3 2 9
fold EC 50 increase, validating this protein as an amphotericin-B efficacy determinant in T. brucei (Fig. 8D ). The impact of Tb927.11.13000 depletion was most pronounced during than 40% and 60% over the same periods. In addition, while exposure to 1.8 µM (>EC 99.9 )
amphotericin-B led to an 80% decline in the induced population over 24 hours, cultures of S6). Depletion of this putative phospholipid-transporting ATPase had no effect on 3 3 8 miltefosine efficacy (Fig. 8E ) confirming its specific contribution to amphotericin-B action.
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Our results reveal that multiple T. brucei flippases drive the efficacy of
amphotericin-B, all of which have syntenic orthologues in Leishmania (Fig. 8A ). Therefore, In the current absence of an effective genome-scale loss-of-function screen in
Leishmania, we speculated that selection of a T. brucei RNAi library would provide insights 3 4 8
into anti-leishmanial drug action, while also revealing novel T. brucei biology. By selecting 3 4 9
our genome-scale BSF T. brucei RNAi library in the current anti-leishmanial drugs followed
by RIT-seq analysis, we identified a panel of putative anti-leishmanial drug efficacy 3 5 1 determinants (Table S1 and Fig. S1 ). SSG and miltefosine selection respectively identified
TbAQP3, an orthologue of the known SSG transporter, and Tb927.11.3350, the T. brucei approach. In addition to these known drug transporters, we validated several novel drug efficacy determinants identified by our selective screens: Tb927.9.6360-80 (paromomycin),
Tb927.5.3560 (miltefosine and amphotericin-B) and Tb927.11.13000 (amphotericin-B).
Our results highlight the role of a lysosomal transporter in paromomycin efficacy,
emphasise the importance of membrane composition in the action of amphotericin-B and
miltefosine, provide insight into the substrate selectivity of the trypanosomatid
aquaglyceroporins, and present several new candidate anti-leishmanial drug efficacy 3 6 1 determinants (Fig. 9 ). T. brucei RNAi library selection in SSG and our subsequent validation experiments transporters of water, glycerol and other small solutes, whose specificity is defined by their 3 6 5 selectivity filter residues. Leishmania AQP1 and the T. brucei proteins, TbAQP1 and
TbAQP3, have the same selectivity filter, NPA/NPA/WGYR, while TbAQP2 possesses a 3 6 7 divergent filter, NSA/NPS/IVLL (39). TbAQP2 is a key drug transporter in T. brucei,
mediating the uptake of pentamidine and melarsoprol, and its loss contributes to clinical 3 6 9 drug resistance (35-37). In addition, TbAQP2 plays an important role in glycerol transport,
as its loss increases parasite sensitivity to alternative oxidase inhibition, which leads to aquaglyceroporins remain unknown, though all three are capable of arsenite and
antimonite transport in yeast and Xenopus heterologous expression systems (49). In
contrast, our data demonstrate that in T. brucei these transporters are selective for
arsenic-containing melarsoprol (TbAQP2; (35)) and antimony-containing, SSG (TbAQP3). RNAi library, with the remaining 28 high confidence hits constituting only 9% of mapped
reads. This locus encodes a set of closely related MFST proteins, at least one of which 3 9 1 localises to the lysosome, and has previously been associated with suramin efficacy (24). In contrast to paromomycin, several other endocytic pathway proteins, including three (24). This led to the proposal that proteolytic processing in the lysosome releases suramin
from bound proteins, enabling neutralisation in the acidic environment or association with an alternative endogenous carrier and escape to the cytoplasm via one or more of the 3 9 7
lysosomal MFSTs (54). In contrast, the absence of hits targeting other endocytic components following paromomycin RNAi library selection suggests little reliance on the overexpression reduces sensitivity to multi-drug exposure (26); these also lack an obvious 4 2 6 connection to oxidative defence. Therefore, rather than being dependent on the increase amphotericin-B/miltefosine combination therapy in treating VL (58, 59). In contrast to the other anti-leishmanial drug efficacy determinants described both and enabling TbVAMP7B-depleted parasites to persist at these drug concentrations. Our data shows that T. brucei has limited tolerance for TbVAMP7B depletion, presumably T. brucei and Leishmania (43), suggesting that Leishmania parasites will also be sensitive The MT and Ros3 localise to the plasma membrane in Leishmania (18), whereas the T. an indirect role in drug action, possibly through changes in membrane composition and
transit through the endosomal system ( Fig. 9 ). Amphotericin-B acts by binding membrane
ergosterol (67), leading to the formation of ion-permeable channels and downstream drive the anti-leishmanial action of amphotericin-B.
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In summary, using our genome-scale BSF T. brucei RNAi library we have identified potential resistance mechanisms, and should facilitate the development of improved
therapies, as well as surveillance for drug-resistant parasites. MITat1.2/2T1 BSF T. brucei (71) were maintained in HMI11 (Invitrogen, LifeTech)
supplemented with 10% foetal calf serum (Sigma) at 37°C/5% CO 2 . Transfection was
carried out in either cytomix or Tb-BSF buffer (72), for integration at the 2T1 'landing pad' 4 9 9
(71, 73) or Tb927.9.6360-80, respectively, using a Nucleofector (Lonza) set to programme
X-001. Transformants were selected in 2.5 µg.ml -1 hygromycin, 2 µg.ml -1 puromycin or 10 µg.ml -1 phleomycin and 5 µg.ml -1 blasticidin (34). For growth assays, cultured BSF T.
brucei were seeded at ~10 5 cells.ml -1 , counted using a haemocytometer, and diluted back
every 24 hours, as necessary, for three days in the absence of antibiotics. All selective
antibiotics were purchased from Invivogen. stibogluconate, GSK; paromomycin, Sigma; miltefosine, Paladin; amphotericin-B, E R each anti-leishmanial drug at 1-3X EC 50 . Cell density was assessed daily using a 5 2 5
haemocytometer and diluted to no less than 20 million cells in 100 ml media; induction and
anti-leishmanial drug selection were maintained throughout. Once robust growth had been
achieved for at least two days, genomic DNA was prepared for RNAi target identification.
The RNAi cassettes remaining in the anti-leishmanial-selected RNAi libraries were
amplified from genomic DNA using the LIB2F/LIB2R primers and sequenced on an
Illumina HiSeq platform at the Beijing Genome Institute.
The sequenced RNAi target fragments were mapped against the T. brucei strain
TREU927 reference genome (release 6.0), as described (34). Briefly, mapping was carried
out using Bowtie2 (75) set to 'very sensitive local' alignment and output SAM files were construct-specific 14-base barcode were identified using a custom script (34), and
corresponded to at least 22% of reads from each selected RNAi library. This subset of 5 3 8
reads were mapped against the TREU927 reference genome, as above. Plots were 5 3 9 generated using the Artemis graph tool and processed in Adobe Photoshop Elements 8.0.
Stacks of reads that included the 14-base barcode on the positive strand were used to
define RNAi target fragment junctions and to assign high-confidence hits as those depth variations when comparing RNAi library sequencing outputs.
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Alignments were carried out in Clustal Omega constructed using the GO analysis tool at http://tritrypdb.org. loop RNAi constructs targeting Tb927. 11.6680 (AAT15), Tb927.11.13000, Tb927.11.3350,
Tb927.5.3560 (TbVAMP7B) and Tb927.5.3570 were assembled in pRPa-iSL (73). RNAi
targeting fragments were designed using the RNAit primer design algorithm to minimise transfection and targeted integration at the rDNA spacer 'landing pad' locus in 2T1 BSF T. probes were generated by PCR, hybridised and detected according to standard protocols
and the manufacturer's instructions. Sequence data are available as fastq files at the European Nucleotide Archive ERS3348616; miltefosine, ERS3348617; paromomycin, ERS3348618; sodium
stibogluconate, ERS3348619). times (red arrows). Insets: RNAi library-specific PCR. each selective screen were mapped against the TREU927 T. brucei reference genome.
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Red bars correspond to T. brucei orthologues of known Leishmania drug transporters:
AQP2-3, aquaglyceroporin-2-3 locus, Tb927.10.14160-70; MT, miltefosine transporter SSG, sodium stibogluconate; Pmm, paromomycin; Milt, miltefosine; AmB, amphotericin-B. TbAQP3, a T. brucei orthologue of Leishmania AQP1, is selective for sodium were carried out in quadruplicate. Error bars represent standard deviation. WT, T. brucei
wild type for the AQP2-3 locus. The T. brucei lysosomal major facilitator superfamily protein influences the efficacy joining tree comparing representative Leishmania MFST proteins with Tb927.9.6360-80 EC 50 data from three independent biological replicates. Individual growth (E) and EC 50 (F-
H) assays were carried out in triplicate and quadruplicate, respectively. Error bars See Table S2 for further details. Table S1 1 0 3 6
Transcripts represented by >99 RNAi construct-specific barcode-containing reads per 
